Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more
Zivo Bioscience Inc (ZIVO) - Total Assets
Latest total assets as of September 2025: $559.45K USD
Based on the latest financial reports, Zivo Bioscience Inc (ZIVO) holds total assets worth $559.45K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zivo Bioscience Inc - Total Assets Trend (2003–2024)
This chart illustrates how Zivo Bioscience Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zivo Bioscience Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Zivo Bioscience Inc's total assets of $559.45K consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.9% |
| Accounts Receivable | $2.21K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Zivo Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zivo Bioscience Inc's current assets represent 99.5% of total assets in 2024, a decrease from 100.0% in 2003.
- Cash Position: Cash and equivalents constituted 93.9% of total assets in 2024, up from 9.1% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Zivo Bioscience Inc Competitors by Total Assets
Key competitors of Zivo Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Zivo Bioscience Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zivo Bioscience Inc generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Zivo Bioscience Inc is currently not profitable relative to its asset base.
Zivo Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.17 | 0.01 |
| Quick Ratio | 0.08 | 0.17 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.33 Million | $ -2.14 Million | $ -11.23 Million |
Zivo Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Zivo Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.13 |
| Latest Market Cap to Assets Ratio | 10.24 |
| Asset Growth Rate (YoY) | 195.7% |
| Total Assets | $1.64 Million |
| Market Capitalization | $16.83 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Zivo Bioscience Inc's assets at a significant premium ( 10.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Zivo Bioscience Inc's assets grew by 195.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zivo Bioscience Inc (2003–2024)
The table below shows the annual total assets of Zivo Bioscience Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.64 Million | +195.68% |
| 2023-12-31 | $555.72K | -73.82% |
| 2022-12-31 | $2.12 Million | -76.39% |
| 2021-12-31 | $8.99 Million | +3983.12% |
| 2020-12-31 | $220.18K | -40.39% |
| 2019-12-31 | $369.39K | -10.23% |
| 2018-12-31 | $411.51K | -90.23% |
| 2017-12-31 | $4.21 Million | +471.02% |
| 2016-12-31 | $737.29K | +914.44% |
| 2015-12-31 | $72.68K | -28.65% |
| 2014-12-31 | $101.86K | -95.32% |
| 2013-12-31 | $2.17 Million | +829.22% |
| 2012-12-31 | $234.00K | -49.51% |
| 2011-12-31 | $463.49K | +36.35% |
| 2010-12-31 | $339.92K | -15.40% |
| 2009-12-31 | $401.80K | -7.66% |
| 2008-12-31 | $435.14K | +58.32% |
| 2007-12-31 | $274.85K | -14.62% |
| 2006-12-31 | $321.92K | -51.22% |
| 2005-12-31 | $659.94K | +1142.03% |
| 2004-12-31 | $53.13K | +439.65% |
| 2003-12-31 | $9.85K | -- |